Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Shares of Bristol Myers Squibb stock tumbled Monday as investors worried the coronavirus slowdown could stall approval for a key multiple sclerosis drug called ozanimod.

BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug

bluebird bio

BioMarin Pharmaceutical

These biopharma stocks are taking a big hit because of the COVID-19 pandemic.

Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday

Bristol-Myers Squibb (NYSE: BMY) could outperform the broader S&P 500 index, going by trends seen during the 2008 slowdown. It is likely that it could bounce back strongly from the recent lows of around $53 and potentially outperform, when the coronavirus and oil price war crisis winds down.

Bristol-Myers Squibb Stock Set To Outperform S&P 500 Post Coronavirus?

Merck

CDC: Cancer Death Rates Are Declining

Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.

Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC

The drug company will still need to perform confirmatory studies, however.

FDA Approves Bristol Myers Squibb's Liver Cancer Drug Combo

AbbVie

Amgen

Takeda Pharmaceutical

Lawmakers have for years been concerned the U.S. is too reliant on foreign manufacturing of medicine.

Lawmakers pressure Big Pharma on drug supply chains amid coronavirus outbreak

American Airlines

Amazon

Dick's Sporting Goods

United Continental Hlds

Amazon, Dick's Sporting Goods, American Airlines, United Airlines and Bristol-Myers Squibb were our top stock trades for Wednesday.

5 Top Stock Trades for Wednesday: AMZN, DKS, AAL, BMY, UAL

Coronavirus Fears Make Bristol-Myers Squibb A Buy

Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.

Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study

Epizyme

GlaxoSmithKline

On the heels of an FDA approval and with another due soon, investors may want to participate in a biotech that boasts It's

Smart Money Is Clamoring to Own This Cancer-Fighting Biotech

Bristol-Myers said Monday a triple-drug cancer treatment failed in Phase 3 testing — prodding BMY stock to crumble. Bristol-Myers tested the regimen in multiple myeloma.

Bristol-Myers Squibb Tumbles After Cancer Treatment Flops In Key Test

Bristol-Myers Squibb Co. shares BMY, -4.39% slid 4% in premarket trade Monday, after the drug company said a late-stage trial of a treatment for multiple myeloma missed its main goal.

Bristol-Myers shares slide 4% premarket on news of failed trial of multiple myeloma treatment

Agenus

Aphria

Atreca

Bicycle Therapeutics Plc - ADR

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals Inc

Amicus Therapeutics

GW Pharmaceuticals

OrganiGram Holdings Inc.

Pfizer

Arcus Biosciences

Sarepta Therapeutics

The coronavirus induced sell-off has created a number of attractive buying opportunities.

These 14 Stocks Are Stupid Cheap

Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock?

Why Is Bristol-Myers (BMY) Down 10.1% Since Last Earnings Report?

Bank of America

Chubb

Dover

JPMorgan Chase & Co

Southern Company

Travelers

United Technologies

Wells Fargo

Clorox

Coronavirus May Mean Recession: Have Cash, Watch Buffett, Own Berkshire

Bristol-Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.59% move from the prior day.

Bristol-Myers Squibb (BMY) Stock Moves -1.59%: What You Should Know

Bristol-Myers Squibb: Market Uncertainty Makes For A (Potential) Buying Opportunity

Bristol-Myers Squibb (BMY) closed at $59.06 in the latest trading session, marking a -0.87% move from the prior day.

Bristol-Myers Squibb (BMY) Stock Moves -0.87%: What You Should Know

Agnico Eagle Mines

American Electric Power Company

Target

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The Dow Jones industrial average is down a stunning 3,200 points this week, and we have given back almost five months worth of gains in six trading sessions.

The Fed May Have to Lower Rates Soon: Buy These Safe Dividend Stocks Now

Bristol-Myers' Liso-Cel Given Priority Review, Ability To Change Scope Of Treatment

Bausch Health Companies Inc

These three pharma stocks offer safe harbor in a volatile market.

3 Value Stocks to Buy if the Stock Market Implodes

Intuitive Surgical

It's not just their cancer treatments that make these stocks attractive.

3 Cancer Treatment Stocks  to Buy Right Now

Success for the Celgene merger rests heavily on new drug approvals the U.S. Food and Drug Administration could deliver in March.

A Big Month Ahead for the FDA and Bristol-Myers Squibb

Bristol-Myers Squibb Makes Case For Success Of Opdivo With Latest Long-Term Kidney Cancer Data

News for Bristol-Myers Stock (BMY)